RBC Capital reiterated a Sector Perform rating and $36.00 price target on Valeant Pharmaceuticals (NYSE: VRX) following the company's announcement ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments

T. Rowe Price Sues Valeant Pharma (VRX) Alleging 'Fraudulent Scheme' That Cost Investors Billions - DJAugust 18, 2016 10:56 AM Pre-Open Stock Movers 8/18: (SEMI) (CIE) (RPTP) Higher; (EARS) (CERU) (PTLA) LowerAugust 18, 2016 9:25 AM Valeant amends credit facility for second time in six monthsAugust 18, 2016 8:37 AM Valeant Pharma (VRX) Announces Lender Consent for Credit Facility AmendmentAugust 18, 2016 8:01 AM Valeant Pharmaceuticals Receives Lender Consent For Credit Facility AmendmentAugust 18, 2016 8:00 AM Wall St. inches up with energy gain, Wal-MartAugust 18, 2016 7:32 AM Valeant Pharma (VRX) Ramps to Session Highs Following Analyst UpgradeAugust 17, 2016 12:00 PM Notable Analyst Rating Changes 8/17: (INFO) (AVXS) (VRX) Upgraded; (ADS) (CUZ) (ASML) DowngradedAugust 17, 2016 10:12 AM Pre-Open Stock Movers 8/17: (SKYS) (SCYX) (NVIV) Higher; (STEM) ((JASO) (CREE) LowerAugust 17, 2016 9:27 AM Valeant (VRX) volatility flat into upgrade to Overweight at Morgan Stanley August 17, 2016 7:03 AM Morgan Stanley Makes Bullish Call on Valeant (VRX); Rating Raised to 'Overweight'August 17, 2016 6:59 AM